Tag: MONOGRAPH

  • Paraxanthine

    Dimethylxanthine adenosine receptor antagonist and selective cGMP-preferring phosphodiesterase (PDE9) inhibitor

    The principal dimethylxanthine metabolite of caffeine in humans, distinguished from the parent compound and from other methylxanthines by selective inhibition of cGMP-preferring phosphodiesterase 9, potentiation of nitric oxide signaling, ryanodine receptor channel activation, and a favorable safety profile relative to caffeine.

    Abstract

    Paraxanthine (1,7-dimethylxanthine) is the primary metabolite of caffeine in humans, accounting for approximately 80 percent of caffeine biotransformation through hepatic cytochrome P450 1A2 (CYP1A2) catalyzed N3-demethylation. Although structurally an isomer of the naturally occurring dimethylxanthines theophylline (1,3-dimethylxanthine) and theobromine (3,7-dimethylxanthine), paraxanthine is not produced by plants and is encountered in human plasma exclusively as a product of caffeine metabolism. The compound has received escalating research attention since the mid-2000s as a pharmacologically distinct entity rather than a mere intermediate metabolite, with a mechanism of action profile that diverges meaningfully from caffeine at several molecular targets.

    The principal pharmacological activities of paraxanthine are competitive antagonism at adenosine A1 and A2A receptors (with binding affinities comparable to or modestly greater than caffeine), selective inhibition of the cGMP-preferring phosphodiesterase PDE9 (an activity not shared by caffeine, theophylline, or theobromine), potentiation of nitric oxide neurotransmission (a unique property among the naturally occurring methylxanthines), and activation of ryanodine receptor calcium release channels (the mechanism underlying its neuroprotective activity in dopaminergic cell models). The composite pharmacology produces psychostimulant, procognitive, neuroprotective, lipolytic, and ergogenic effects that are quantitatively and qualitatively distinguishable from those of caffeine in both preclinical and clinical studies.

    Pharmacokinetically, paraxanthine is generated in the liver from caffeine with a formation half-life determined by CYP1A2 activity and reaches plasma concentrations that exceed those of the parent compound approximately 8 to 10 hours after caffeine ingestion. The shorter half-life contributes to a cleaner offset of stimulant effects and reduced sleep disruption relative to caffeine at equimolar doses.

    A 2024 study demonstrated superior cognitive maintenance after a 10-kilometer run compared to caffeine, with caffeine-treated subjects committing 31 percent more errors while paraxanthine-treated subjects improved correct responses by approximately 6.8 percent. Preclinical studies in rodents have demonstrated that paraxanthine supplementation increases muscle mass by 14 to 41 percent, forelimb grip strength by 17 percent, and treadmill endurance by 39 percent relative to control. Paraxanthine has also been shown to enhance brain-derived neurotrophic factor (BDNF) levels, elevate hippocampal acetylcholine and dopamine, and provide neuroprotection against MPTP-induced dopaminergic cell death through ryanodine receptor channel activation.

    The safety profile of paraxanthine is favorable relative to caffeine. In vitro genotoxicity and mutagenicity studies are negative. The ingredient has achieved self-affirmed Generally Recognized as Safe (GRAS) status for use in food and beverages in the United States at levels up to 300 mg per serving. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Roxadustat

    Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and 2-oxoglutarate analog

    A first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed by FibroGen for the treatment of anemia in chronic kidney disease, distinguished from conventional erythropoiesis-stimulating agents by its mechanism of HIF-alpha stabilization, endogenous erythropoietin induction, hepcidin suppression, and improved iron homeostasis.

    Abstract

    Roxadustat (FG-4592), the N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine derivative and first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive regulatory approval worldwide, is an orally bioavailable small molecule developed by FibroGen, Inc. for the treatment of anemia associated with chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patient populations. The compound acts by competitively inhibiting the three isoforms of prolyl hydroxylase domain enzymes (PHD1, PHD2, PHD3) that, under normoxic conditions, hydroxylate proline residues on the oxygen-dependent degradation domain of hypoxia-inducible factor alpha subunits (HIF-1alpha and HIF-2alpha), thereby targeting them for von Hippel-Lindau (VHL) E3 ubiquitin ligase-mediated proteasomal degradation. By reversibly occupying the 2-oxoglutarate binding pocket of the PHD enzymes, roxadustat stabilizes HIF-alpha, permitting its nuclear translocation, heterodimerization with HIF-beta (ARNT), and transcriptional activation of hypoxia-responsive element (HRE)-containing target genes. In addition to EPO induction, roxadustat suppresses hepatic hepcidin expression, upregulates duodenal ferroportin and divalent metal transporter 1 (DMT1), increases transferrin receptor expression, and thereby improves iron absorption, mobilization, and utilization, an effect of particular clinical relevance in the iron-restricted erythropoiesis commonly observed in CKD patients with chronic inflammation. Roxadustat received its first global approval in China in December 2018 for dialysis-dependent CKD anemia, followed by approvals in Japan (2019, Astellas Pharma, marketed as Evrenzo), the European Union (August 2021, European Commission), South Korea, and Chile. In the United States, the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration voted against approval in July 2021, citing unresolved cardiovascular safety signals (including increased rates of vascular access thrombosis and deep venous thrombosis in dialysis-dependent populations relative to epoetin alfa) and concerns regarding data integrity in the sponsor’s cardiovascular safety analyses. A large Phase 3 clinical program encompassing the ALPS, ANDES, OLYMPUS, ROCKIES, SIERRAS, HIMALAYAS, and PYRENEES trials demonstrated non-inferiority or superiority to placebo and non-inferiority to epoetin alfa for hemoglobin correction and maintenance across CKD populations, with pooled analyses in incident dialysis patients suggesting a 30 percent reduction in major adverse cardiovascular events (MACE) relative to epoetin alfa. Pharmacokinetics are characterized by rapid oral absorption (Tmax approximately 1 to 2 hours), high plasma protein binding (approximately 99 percent), hepatic metabolism predominantly through CYP2C8 oxidation and UGT1A9 glucuronidation, and an elimination half-life of approximately 12 to 15 hours in CKD patients. Clinically significant drug-drug interactions include increased exposure with CYP2C8 inhibitors (gemfibrozil), reduced absorption with phosphate binders (sevelamer, calcium acetate), and inhibition of BCRP and OATP1B1 transporters leading to elevated statin exposures when co-administered. Beyond anemia, preclinical and early clinical evidence suggests potential renoprotective, anti-inflammatory, and cardioprotective properties mediated through HIF-dependent pathways, including protection against ischemia-reperfusion injury, suppression of NF-kappaB-driven inflammatory cytokines, and modulation of lipid metabolism. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Dapoxetine

    Short-acting selective serotonin reuptake inhibitor (SSRI) with rapid-onset, rapid-elimination pharmacokinetics developed for on-demand treatment of premature ejaculation

    A naphthalene-derived phenylpropylamine SSRI originally developed at Eli Lilly as an antidepressant candidate, repositioned as the first and only oral pharmacotherapy specifically approved for on-demand treatment of premature ejaculation, distinguished from conventional SSRIs by rapid absorption, short initial half-life, and suitability for event-based rather than chronic dosing.

    Abstract

    Dapoxetine (LY 210448) is a short-acting selective serotonin reuptake inhibitor (SSRI) and the first oral pharmacotherapy specifically developed and approved for the on-demand treatment of premature ejaculation (PE) in adult men aged 18 to 64 years. Originally synthesized at Eli Lilly and Company as an antidepressant candidate in the late 1980s, the compound was shelved after failing to demonstrate sufficient efficacy in depression, subsequently licensed to Pharmaceutical Product Development (PPD) in 2003, and then advanced through Phase 3 clinical development by ALZA Corporation (a Johnson and Johnson subsidiary) for the PE indication. Dapoxetine received its first regulatory approvals in Finland and Sweden in 2009 under the trade name Priligy and has since been registered in over 60 countries across Europe, Asia, Latin America, and Oceania. The compound has not been approved by the United States Food and Drug Administration, which issued a not-approvable letter in 2005 citing the need for additional efficacy and safety data.

    The pharmacological mechanism of dapoxetine is inhibition of the serotonin transporter (SERT) at both peripheral and central sites, increasing serotonin availability at postsynaptic receptors in the ejaculatory pathway. Preclinical electrophysiology studies in anaesthetized rats demonstrated that dapoxetine inhibits the ejaculatory expulsion reflex at a supraspinal level, specifically modulating activity of lateral paragigantocellular nucleus (LPGi) neurons that project to spinal ejaculatory motor centers. The compound exhibits high selectivity for the serotonin transporter over the norepinephrine and dopamine transporters, with Ki values of approximately 1.0 nM for SERT, 66 nM for the norepinephrine transporter, and greater than 1000 nM for the dopamine transporter.

    The critical pharmacokinetic distinction of dapoxetine from conventional SSRIs (paroxetine, fluoxetine, sertraline, citalopram) is its rapid absorption and elimination profile. After oral administration, dapoxetine reaches maximum plasma concentration (Cmax) within approximately 1.0 to 1.3 hours, with an initial distribution half-life of 1.3 to 1.4 hours and a terminal elimination half-life of 18.7 to 21.9 hours. Oral bioavailability is approximately 42 percent, with substantial interindividual variability (range 15 to 76 percent) attributable to first-pass hepatic metabolism. Metabolism proceeds through CYP3A4, CYP2D6, and flavin-containing monooxygenase 1 (FMO1) pathways, producing dapoxetine N-oxide (inactive), N-desmethyldapoxetine (active), and N,N-didesmethyldapoxetine (active) as the principal circulating metabolites. Plasma protein binding exceeds 99 percent.

    Integrated analysis demonstrated that mean intravaginal ejaculatory latency time (IELT) increased from a baseline of 0.9 minutes to 3.2 minutes with dapoxetine 30 mg and 3.5 minutes with dapoxetine 60 mg, compared to 1.9 minutes with placebo. Statistically significant improvements were observed across all patient-reported outcome domains including ejaculatory control, satisfaction with sexual intercourse, ejaculation-related personal distress, and interpersonal difficulty. The safety profile is consistent with the SSRI pharmacological class; the most common adverse events are nausea (8.7 to 20.1 percent), dizziness (5.8 to 10.9 percent), headache (5.6 to 8.8 percent), diarrhea (3.9 to 6.8 percent), and somnolence. A specific safety concern is vasovagal-mediated syncope, observed at rates of 0.06 percent with 30 mg and 0.23 percent with 60 mg compared to 0.05 percent with placebo. Dapoxetine is contraindicated with potent CYP3A4 inhibitors, monoamine oxidase inhibitors, other serotonergic agents, and in patients with significant cardiovascular disease or a history of syncope.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • PP-405

    First-in-class dual mitochondrial pyruvate carrier (MPC1/MPC2) inhibitor for topical hair follicle stem cell activation

    A proprietary small-molecule mitochondrial pyruvate carrier inhibitor developed at UCLA and advanced by Pelage Pharmaceuticals as a topical therapy for androgenetic alopecia, distinguished from existing treatments by a first-in-class metabolic mechanism that reactivates quiescent hair follicle stem cells through lactate dehydrogenase upregulation.

    Abstract

    PP-405 is a first-in-class, topically administered small-molecule inhibitor of the mitochondrial pyruvate carrier (MPC), under clinical development by Pelage Pharmaceuticals for the treatment of androgenetic alopecia (AGA) in men and women. The compound acts as a dual inhibitor of MPC1 and MPC2, blocking pyruvate import into the mitochondrial matrix and thereby redirecting cellular metabolism toward glycolysis with concomitant elevation of intracellular lactate through stimulation of lactate dehydrogenase (LDH) activity. This metabolic shift activates quiescent hair follicle stem cells (HFSCs) residing in the bulge region of the hair follicle, driving telogen-to-anagen transition and the initiation of new hair growth cycles. The mechanistic rationale derives from the seminal Flores et al. (2017) demonstration in Nature Cell Biology that HFSCs utilize glycolytic metabolism, produce substantially more lactate than other epidermal cell populations, and that genetic deletion of lactate dehydrogenase A (Ldha) prevents HFSC activation, while genetic deletion of mitochondrial pyruvate carrier 1 (Mpc1) accelerates the hair cycle in murine models [1]. The medicinal chemistry program at UCLA, led by Michael Jung in collaboration with Heather Christofk and William Lowry, subsequently developed a series of novel MPC inhibitors based on the cyano-cinnamate pharmacophore, advancing from the prototype UK-5099 through iterative structure-activity relationship optimization to produce compounds with markedly enhanced potency and skin-penetration characteristics [2].

    PP-405 is the proprietary clinical candidate selected from this program. Its chemical structure has not been publicly disclosed; Pelage Pharmaceuticals has confirmed that PP-405 is structurally distinct from JXL-069, the published 7-azaindole-bearing MPC inhibitor (CAS 2260696-63-5) described in the Jeong et al. (2021) Journal of Medicinal Chemistry report, though both compounds originate from the same UCLA medicinal chemistry effort [2, 3]. The compound has been engineered for preferential skin penetration over systemic absorption, with reported selectivity of approximately 1,000-fold for dermal over plasma distribution. In clinical pharmacokinetic assessments, no PP-405 was detected in circulating blood plasma following topical scalp application at the clinical dose of 0.05%, and the compound is reported to be unstable in blood, providing an intrinsic pharmacokinetic safety margin against systemic exposure [4, 5].

    Clinical development has proceeded through a Phase 1 safety and pharmacokinetic study completed in January 2024 and a Phase 2a randomized, multicenter, double-blind, vehicle-controlled efficacy trial (NCT06393452) in 78 adults with androgenetic alopecia. The Phase 1 study demonstrated proof of mechanism through scalp biopsy analysis showing statistically significant upregulation of Ki67-positive proliferating cells in the hair follicle bulge region after seven days of 0.05% PP-405 topical application, with concurrent increases in LDH activity in hair follicle stem cells [4]. Ex vivo human scalp tissue experiments presented at the American Academy of Dermatology 2024 Annual Meeting confirmed that single topical applications of PP-405 at concentrations as low as 0.006% increased LDH activity in HFSCs within 24 hours [4]. The Phase 2a trial reported that 31% of PP-405-treated men with higher-grade hair loss demonstrated greater than 20% increases in hair density at eight weeks following four weeks of daily treatment, compared with 0% in the vehicle-control group; additionally, PP-405 induced new hair growth in areas where no hair was previously present, suggesting regenerative capacity beyond the follicle-preserving activity of existing therapies [5, 6]. The compound was well tolerated with no treatment-related systemic adverse events and no detectable systemic absorption.

    Pelage Pharmaceuticals plans to initiate Phase 3 registration trials in 2026 to evaluate the safety and efficacy of PP-405 in both men and women with androgenetic alopecia. If successful, regulatory approval could be anticipated in the 2027 to 2029 timeframe. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Pinealon

    Synthetic bioregulatory tripeptide (Glu-Asp-Arg) with proposed epigenetic neuromodulatory activity

    A synthetic tripeptide bioregulator derived from the pineal gland peptide fraction, investigated as a neuroepigenetic modulator of gene expression with reported neuroprotective, antioxidant, and geroprotective activity in preclinical oxidative stress, ischemia, and neurodegeneration models.

    Abstract

    Pinealon (EDR peptide; L-glutamyl-L-aspartyl-L-arginine) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson as part of a multigenerational program to identify tissue-specific short-chain peptides capable of modulating gene expression through direct interaction with chromatin. The compound was identified as one of the shortest biologically active sequences within Cortexin, a complex peptide fraction extracted from bovine cerebral cortex tissue that has been used clinically in several post-Soviet jurisdictions for the treatment of traumatic brain injury, ischemic stroke, and cognitive impairment. Pinealon was subsequently synthesized as a standalone tripeptide and advanced through a series of in vitro and in vivo investigations spanning antioxidant activity, neuroprotection, serotonin biosynthesis regulation, dendritic spine preservation in Alzheimer’s disease models, and preliminary open-label clinical observations in elderly patients with cognitive decline and in patients recovering from craniocerebral trauma.

    The proposed mechanism of action is unconventional relative to classical receptor-mediated peptide pharmacology. Due to its low molecular weight (418.41 g/mol) and cationic character, Pinealon is reported to penetrate lipid bilayers and nuclear membranes without requiring surface receptor engagement, gaining direct access to chromatin. Molecular modeling and in vitro binding studies from the Khavinson laboratory have identified complementary binding sites in the promoter regions of several genes relevant to neuroprotection and neurodegeneration, including TPH1 (tryptophan hydroxylase 1, the rate-limiting enzyme in serotonin biosynthesis), SOD2 (mitochondrial superoxide dismutase), GPX1 (glutathione peroxidase 1), PPARA and PPARG (peroxisome proliferator-activated receptor alpha and gamma), CASP3 (caspase-3), and APOE (apolipoprotein E). The proposed binding occurs at specific DNA sequences, principally d(CCTGCC)2 and d(CCAGC)2, through sequence-specific steric and electrostatic complementarity with the major groove of double-stranded DNA. The functional consequence is reported to be destabilization of local DNA secondary structure, alteration of histone modification patterns, and increased accessibility of regulatory regions to transcription factors, resulting in upregulation of neuroprotective gene products and downregulation of pro-apoptotic pathways.

    Preclinical pharmacology studies, conducted predominantly by the Khavinson group and affiliated Russian laboratories, have reported that Pinealon produces dose-dependent suppression of reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells; increases cell viability under oxidative stress conditions; delays ERK1/2 activation in neurons exposed to homocysteine; reduces caspase-3 expression and p53 protein synthesis in brain tissue; increases serotonin synthesis in neuronal cultures of rat cerebral cortex; normalizes superoxide dismutase and glutathione peroxidase activity in the brains of hypoxia-sensitive rats; prevents the loss of mushroom-shaped dendritic spines in hippocampal neurons from 5xFAD transgenic mice (a model of familial Alzheimer’s disease); and protects rat offspring from prenatal hyperhomocysteinemia-induced cognitive deficits. In an open-label clinical observation in 72 patients with traumatic brain injury, addition of Pinealon to standard rehabilitation therapy improved memory function in approximately 59 percent of patients.

    No completed, peer-reviewed randomized controlled trial of Pinealon has been published in English-language indexed journals as of the date of this monograph. No Phase 1 formal safety study, no Phase 2 efficacy trial, and no Phase 3 registration study exist in any population. The compound has no approved indication in any jurisdiction recognized by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Virtually all published Pinealon research originates from the Khavinson laboratory and closely affiliated institutions; independent replication by Western academic laboratories is absent. The chromatin-interaction model, while supported by computational molecular modeling and fluorescence microscopy studies from the originating group, has not been independently validated by structural biology methods (X-ray crystallography, cryo-electron microscopy) at the resolution required to confirm the proposed binding geometry. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Elafibranor

    Dual peroxisome proliferator-activated receptor alpha/delta (PPARalpha/delta) agonist with additional PPARgamma activity

    A first-in-class dual PPARalpha/delta agonist developed by Genfit for hepatic steatoinflammatory and cholestatic liver diseases, granted FDA accelerated approval in June 2024 as Iqirvo for the treatment of primary biliary cholangitis in adults with inadequate response or intolerance to ursodeoxycholic acid.

    Abstract

    Elafibranor (GFT505) is a synthetic phenoxyalkanoic acid derivative and dual agonist of the peroxisome proliferator-activated receptor alpha (PPARalpha) and peroxisome proliferator-activated receptor delta (PPARdelta), with additional lower-potency agonist activity at the peroxisome proliferator-activated receptor gamma (PPARgamma). The compound activates PPARalpha with an EC50 of approximately 45 nanomolar and PPARdelta with an EC50 of approximately 175 nanomolar, producing a composite pharmacological profile that modulates hepatic fatty acid beta-oxidation, triglyceride metabolism, high-density lipoprotein cholesterol, bile acid synthesis and transport, glucose homeostasis, and macrophage-mediated hepatic inflammation through coordinated transcriptional regulation at both receptor subtypes. Elafibranor and its principal active metabolite GFT1007, formed by hydrolysis of the parent compound, both contribute to the pharmacological activity. On June 10, 2024, the United States Food and Drug Administration granted accelerated approval to elafibranor (trade name Iqirvo, marketed by Ipsen) for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. European Union authorization followed in September 2024, and the United Kingdom National Institute for Health and Care Excellence (NICE) recommended elafibranor for National Health Service use in October 2024. Pharmacokinetics are characterized by high plasma protein binding (approximately 99.7 percent), a large apparent volume of distribution (approximately 4,731 liters), a long elimination half-life of the parent compound (approximately 60 to 70 hours), and metabolism of GFT1007 through CYP2C8, UGT1A3, and UGT2B7. The compound is contraindicated in decompensated cirrhosis and complete biliary obstruction and carries a warning for embryo-fetal toxicity. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • PPAP-HCl

    Catecholaminergic activity enhancer (CAE) and dopamine transporter reuptake inhibitor derived from the phenylalkylamine/substituted amphetamine scaffold

    Abstract

    PPAP-HCl, the hydrochloride salt of (-)-(R)-1-phenyl-2-propylaminopentane, is an experimental catecholaminergic activity enhancer (CAE) compound originally synthesized by Jozsef Knoll and colleagues at Semmelweis University in Budapest in the late 1980s as a structural derivative of selegiline (L-deprenyl) designed to retain the catecholaminergic enhancer activity of the parent compound while eliminating its monoamine oxidase (MAO) inhibitory property. The compound occupies a mechanistically distinct position in the catecholaminergic pharmacology space: at low-to-moderate concentrations, PPAP potentiates the impulse-propagation-mediated (action-potential-dependent) release of dopamine and norepinephrine from catecholaminergic nerve terminals without producing the uncontrolled, impulse-independent monoamine efflux characteristic of amphetamine and methamphetamine. This “enhancer” mechanism, first formally described by Knoll in 1992 and subsequently elaborated in a series of publications through 2005, operates independently of MAO inhibition, presynaptic autoreceptor blockade, and classical reuptake inhibition, and instead potentiates the vesicular exocytotic release event coupled to the arriving action potential. Recent pharmacological characterization reported in 2025 has expanded the mechanistic profile by demonstrating that PPAP also acts as a potent dopamine transporter (DAT) reuptake inhibitor with an IC50 of 57.5 nM, a norepinephrine transporter (NET) inhibitor at 571 nM, and a weak serotonin transporter (SERT) inhibitor at 19,000 nM, placing it in a dual-mechanism category that combines enhancer activity with catecholamine reuptake inhibition. Additional evidence suggests that PPAP and related synthetic enhancer compounds may exert their catecholaminergic effects through agonism at trace amine-associated receptor 1 (TAAR1), an intracellular G-protein-coupled receptor that modulates vesicular dopamine release through protein kinase C (PKC)-mediated phosphorylation of exocytotic machinery.

    The therapeutic index in animal models exceeds that of amphetamine. Structure-activity relationship studies identified the (R)-enantiomer as the pharmacologically active form, while the racemic mixture (designated MK-306) retains partial activity. PPAP served as the reference catecholaminergic activity enhancer compound in the Knoll laboratory and led directly to the development of the more potent and serotonergically active successor compound BPAP [(-)1-(benzofuran-2-yl)-2-propylaminopentane] in 1999. PPAP has been proposed as a candidate for clinical development in depression, attention deficit hyperactivity disorder (ADHD), and Alzheimer’s disease, though no human clinical trials have been completed or published. The compound is not approved by any regulatory authority for therapeutic use and is available exclusively as a research-grade preparation. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • ACD856

    Triazinetrione positive allosteric modulator of tropomyosin receptor kinases (TrkA, TrkB, TrkC) potentiating neurotrophin signaling

    A first-in-class triazinetrione pan-Trk positive allosteric modulator developed by AlzeCure Pharma that enhances BDNF and NGF signaling for the treatment of cognitive dysfunction in Alzheimer’s disease, with additional preclinical support for depression, traumatic brain injury, and sleep disorders.

    Abstract

    ACD856 is a novel, orally bioavailable triazinetrione compound functioning as a positive allosteric modulator (PAM) of the tropomyosin receptor kinases TrkA, TrkB, and TrkC, the principal signal-transducing receptors for the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3), respectively [1, 2]. The compound was identified through a high-throughput screening campaign of approximately 25,000 compounds and structurally optimized from the veterinary antiparasitic triazinetrione scaffold shared by toltrazuril and ponazuril (ACD855), with the critical improvement of a substantially shortened elimination half-life suitable for once-daily human dosing [3, 4]. ACD856 potentiates the tropomyosin receptor kinases with EC50 values of 382 nM (TrkA), 295 nM (TrkB), and approximately 330 nM (TrkC), and exhibits additional positive allosteric modulation of the insulin-like growth factor 1 receptor (IGF1R) and fibroblast growth factor receptor 1 (FGFR1) [1, 5]. The mechanism of action is distinct from orthosteric Trk agonism: ACD856 binds the intracellular kinase domain of Trk receptors and increases the maximal catalytic velocity (Vmax) of the kinase, thereby amplifying endogenous neurotrophin signaling rather than substituting for it [2, 6]. This allosteric mechanism preserves the spatiotemporal specificity of native neurotrophin activity, a property expected to confer a more favorable safety profile than direct agonist approaches that have historically been limited by pain, hyperalgesia, and off-target proliferative effects.

    In preclinical pharmacology, ACD856 has demonstrated reversal of scopolamine-induced and dizocilpine (MK-801)-induced memory impairment in passive avoidance and novel object recognition tasks in mice, restoration of age-related memory deficits in 21-month-old mice to the performance level of young animals following single-dose administration, neuroprotection against amyloid-beta(1-42)-induced synaptotoxicity in primary cortical neurons, enhancement of NGF-stimulated neurite outgrowth in PC12 cells, elevation of BDNF protein levels in the brains of aged mice following repeated dosing, and sustained antidepressant-like effects in the forced swim test persisting up to seven days after the last dose [5, 7, 8]. The compound also enhanced mitochondrial ATP production under energy-deprived conditions, increased phosphorylation of TrkB and ERK1/2 in cortical neurons, elevated hippocampal concentrations of serotonin, noradrenaline, and dopamine by in vivo microdialysis, and increased expression of the presynaptic protein SNAP25, collectively indicating a broad neuroprotective and neuroplasticity-promoting pharmacological profile [5, 7].

    ACD856 has completed two Phase 1 clinical studies in healthy volunteers. AlzeCure Pharma has received a EUR 2.5 million grant from the European Innovation Council to conduct a Phase IIa clinical study of ACD856 in Alzheimer’s disease, with higher doses to be evaluated based on the favorable Phase 1 safety profile [12]. Additional indications under preclinical investigation include depressive disorders, traumatic brain injury, sleep disorders, and postoperative cognitive dysfunction.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Emodin

    Natural anthraquinone derivative with multi-target anti-inflammatory, antitumor, and metabolic regulatory activity

    A 1,3,8-trihydroxy-6-methylanthraquinone isolated from Rheum palmatum and related Polygonaceae species, characterized by pleiotropic pharmacology spanning NF-kappaB inhibition, AMPK activation, kinase modulation, and broad-spectrum antimicrobial activity, with longstanding traditional use and emerging preclinical validation across oncology, metabolic disease, and inflammatory indications.

    Abstract

    Emodin (1,3,8-trihydroxy-6-methylanthraquinone; CAS 518-82-1) is a naturally occurring anthraquinone derivative present in the roots and rhizomes of multiple medicinal plant species, most notably Rheum palmatum L. (Chinese rhubarb), Polygonum cuspidatum (Japanese knotweed), Polygonum multiflorum (He Shou Wu), Cassia obtusifolia, and Aloe vera. The compound has been a constituent of traditional Chinese medicine preparations for over two millennia, with rhubarb first recorded in the Shen Nong Ben Cao Jing, the earliest systematic pharmacopoeia of traditional Chinese medicine. Modern pharmacological investigation has revealed emodin to be a pleiotropic bioactive molecule operating through multiple convergent signaling pathways, including inhibition of nuclear factor kappa B (NF-kappaB) transcriptional activity, activation of AMP-activated protein kinase (AMPK), suppression of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) axis, modulation of peroxisome proliferator-activated receptor gamma (PPARgamma), and direct inhibition of casein kinase II (CKII) and the protein tyrosine kinase p56lck. These molecular activities produce a composite pharmacological profile encompassing anti-inflammatory, antitumor, antiviral, antibacterial, antifibrotic, hepatoprotective (at low doses), antidiabetic, and immunomodulatory effects demonstrated across extensive in vitro and in vivo preclinical models.

    The antitumor activity of emodin has been characterized in cell culture and rodent xenograft models against pancreatic, hepatocellular, breast, lung, colorectal, and prostate carcinomas, with mechanisms including induction of caspase-dependent apoptosis, cell cycle arrest at the G2/M checkpoint, suppression of matrix metalloproteinase-mediated invasion, inhibition of angiogenesis through vascular endothelial growth factor downregulation, and reversal of gemcitabine resistance through IKKbeta/NF-kappaB pathway suppression. The anti-inflammatory profile operates primarily through suppression of NF-kappaB-driven proinflammatory cytokine release (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) and through NLRP3 inflammasome inhibition. Antiviral activity has been demonstrated against more than ten viral species in vitro and in vivo, including herpes simplex virus types 1 and 2, influenza A virus, coxsackievirus B3, hepatitis B virus, and SARS-CoV. Antibacterial activity is notable against Gram-positive organisms, with minimum inhibitory concentrations against Staphylococcus aureus and Mycobacterium tuberculosis in the low-micromolar range.

    The principal pharmacokinetic limitation of emodin is extremely poor oral bioavailability, approximately 3 percent in rodent models, attributable to rapid and extensive phase II glucuronidation by UDP-glucuronosyltransferases (UGT1A1, UGT1A9, UGT2B7) in both intestinal epithelium and hepatocytes, with additional contributions from CYP1A2 and CYP2E1 oxidative metabolism. Approximately 56 percent of an oral dose is unabsorbed and excreted in feces as parent compound. This pharmacokinetic barrier has substantially limited clinical translation despite extensive preclinical efficacy data. Strategies to overcome poor bioavailability include co-administration with the glucuronidation inhibitor piperine (which produces a 221 percent increase in area under the curve in rodent models), nanoparticle encapsulation, liposomal formulation, polymeric lipid hybrid nanoparticles, and solid lipid nanoparticle delivery systems.

    Toxicological evaluation has identified dose-dependent hepatotoxicity, nephrotoxicity, and reproductive toxicity at sustained high doses. Hepatotoxicity is mediated in part through inhibition of hepatocyte nuclear factor 4 alpha expression and consequent downregulation of UGT2B7, creating a paradoxical positive feedback loop in which high-dose emodin impairs its own principal detoxification pathway. Nephrotoxicity occurs through induction of apoptosis in proximal tubular epithelial cells via PPARgamma-related mitochondrial pathways. Reproductive toxicity includes disruption of testicular gene expression and inhibition of human sperm calcium signaling and tyrosine phosphorylation in vitro. The compound is not approved as a pharmaceutical agent by any major regulatory authority. It is classified as a dietary supplement ingredient and research compound. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • PRL-8-53

    Substituted phenethylamine benzoate ester with hypermnesic (memory-enhancing) activity and mixed dopaminergic-cholinergic-serotonergic pharmacology

    Abstract

    PRL-8-53 (methyl 3-[2-[benzyl(methyl)amino]ethyl]benzoate hydrochloride) is a synthetic substituted phenethylamine and benzoate ester first synthesized by Nikolaus R. Hansl at Creighton University in the early 1970s as part of a systematic exploration of amino ethyl meta-benzoic acid esters for spasmolytic and psychotropic activity. The magnitude of the retention enhancement was substantial: subjects in the over-30 subgroup demonstrated approximately 108 percent improvement in 24-hour recall and 152 percent improvement in one-week recall relative to their placebo performance, with most P values better than 0.01 and some better than 0.001. The compound did not significantly alter visual reaction time or motor control at the studied dose, suggesting a selective cognitive action rather than generalized central nervous system stimulation.

    The molecular pharmacology of PRL-8-53 remains incompletely characterized. Preclinical evidence from Hansl’s laboratory and from the patent literature (US 3,870,715; granted March 11, 1975) indicates that the compound potentiates dopaminergic neurotransmission, partially inhibits serotonergic activity, and displays possible cholinergic properties. In animal models, PRL-8-53 reverses reserpine-induced catatonia and ptosis, improves avoidance learning in conditioned response paradigms, and exhibits spasmolytic activity against acetylcholine-, barium chloride-, and histamine-induced smooth muscle contraction.

    Despite these promising early findings, no additional controlled human studies have been published since the 1978 report. The compound’s development was interrupted by Hansl’s retirement from Creighton University and a 1985 institutional dispute that resulted in the loss of stored experimental materials. The patent expired in approximately 1992, placing the compound in the public domain. Formal pharmacokinetic characterization in humans has not been published; the plasma elimination half-life is estimated at 2 to 4 hours on the basis of the compound’s structural properties and the time course of cognitive effects observed in the Hansl study. The metabolic pathways, routes of elimination, plasma protein binding, and blood-brain barrier penetration characteristics remain uncharacterized. PRL-8-53 is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers at greater than 98 percent purity; investigators should obtain independent analytical confirmation of identity and purity on every lot. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.